This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Adam's Most Recent Article

Intra-Cellular Keeps Investors in Dark About Schizophrenia Drug Study

07/31/15 - 09:36 AM EDT

Investors asking Intra-Cellular for a copy of the scientific poster needed to conduct proper due diligence on ITI-007 are told they can't have it.

read more >

Other Articles by Adam

Free Reports

MannKind Afrezza Sales Underwhelming Again, Sanofi Reports MannKind Afrezza Sales Underwhelming Again, Sanofi Reports

07/30/15 - 11:03 AM EDT

The only saving grace is that no one, not even the most Kool-Aid-drinking MannKind supporter, is surprised by Afrezza's poor sales.

read more >
MannKind Relies on 'Death Spiral' Financing to Help Settle Looming Debt MannKind Relies on 'Death Spiral' Financing to Help Settle Looming Debt

07/29/15 - 10:33 AM EDT

MannKind isn't at risk of shutting down imminently because of the death-spiral convert, but the company was forced into a weakened negotiating position because Afrezza is selling poorly.

read more >
Gilead Q2 Earnings: KAPOW! BAM! BOOM! (Yes, That Good) Gilead Q2 Earnings: KAPOW! BAM! BOOM! (Yes, That Good)

07/28/15 - 04:15 PM EDT

Gilead Sciences will not be blamed for a cooling of the biotech bull market, if any such thing exists.

read more >
Struggling Sanofi Sends Cancer SOS to Regeneron and Another Vanity Biotech IPO Launches Struggling Sanofi Sends Cancer SOS to Regeneron and Another Vanity Biotech IPO Launches

07/28/15 - 10:23 AM EDT

It's a day that ends in "day," which means cancer immunotherapy is dominating the biotech news.

read more >
Gilead Can Soothe Biotech Investor Fears with Great 2Q Earnings Gilead Can Soothe Biotech Investor Fears with Great 2Q Earnings

07/27/15 - 12:42 PM EDT

Investor confidence in biotech stocks is shaky following last week's Biogen blow-up, making Tuesday's Gilead earnings even more important.

read more >
Biogen's Possible Takeout Targets and Other Key Questions After Blow-Up Biogen's Possible Takeout Targets and Other Key Questions After Blow-Up

07/27/15 - 10:30 AM EDT

After cutting its revenue growth forecast, will Biogen buy itself back into investors' good graces?

read more >
Xoma Is a Biotech Zombie in Need of a Kill Shot to the Head Xoma Is a Biotech Zombie in Need of a Kill Shot to the Head

07/22/15 - 10:41 AM EDT

After 34 years in existence, Xoma still can't develop a drug successfully on its own.

read more >
Eli Lilly's Solanezumab Is the Alzheimer's Drug Equivalent of the Internet Dress Eli Lilly's Solanezumab Is the Alzheimer's Drug Equivalent of the Internet Dress

07/22/15 - 07:00 AM EDT

Lilly uses a new but contentious methodology to suggest treatment benefit from its experimental Alzheimer's drug.

read more >
FDA Closing In on November Expert Panel Date for BioMarin, Sarepta Drugs FDA Closing In on November Expert Panel Date for BioMarin, Sarepta Drugs

07/20/15 - 02:10 PM EDT

Biotech investors, circle November 23 and 24 on your calendars. Use a thick black marker. This will be an epic event for biotech investors.

read more >
Page 1 of 339
< Previous
Top Rated Stocks Top Rated Funds Top Rated ETFs